Cagent Vascular

Cagent Vascular is a commercial-stage medical device innovator focused on transforming vessel preparation in peripheral vascular interventions. Its core technology, Serration Remodeling Therapy (SRT), uses a serrated balloon catheter to apply controlled, low-pressure point force to arterial lesions, aiming to reduce vessel recoil, minimize dissections, and decrease the need for bailout stenting. With its Serranator product line already on the market and supported by prospective clinical data, the company is targeting the large and growing market for peripheral angioplasty by positioning its technology as a new standard of care. Cagent is expanding its product portfolio and actively conducting comparative clinical studies to further validate its approach.

Serration Technology / Serration Remodeling Therapy (SRT): A balloon catheter platform using longitudinal stainless steel serration strips to apply controlled, low-pressure point force to arterial lesions. This aims to create a predictable line of weakness in the vessel wall to optimize lumen gain, mitigate recoil, and minimize dissection compared to traditional angioplasty.

Cagent competes in the crowded peripheral vascular device market against dominant players like Boston Scientific, Medtronic, Abbott, and Philips, who offer plain balloons, drug-coated balloons (DCBs), stents, and atherectomy systems. Its technology must compete against the established standard (POBA) and the growing adoption of DCBs. Cagent's strategy is to position the Serranator as a superior preparation tool that can be used alone or potentially in combination with other therapies like DCBs.